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ABSTRACT
Around, 30–40% of HER2-positive breast cancers do not show substantial clinical 
benefit from the targeted therapy and, thus, the mechanisms underlying resistance 
remain partially unknown. Interestingly, ERBB2 is frequently co-amplified and  
co-expressed with neighbour genes that may play a relevant role in this cancer 
subtype. Here, using an in silico analysis of data from 2,096 breast tumours, we reveal 
a significant correlation between Gasdermin B (GSDMB) gene (located 175 kilo bases 
distal from ERBB2) expression and the pathological and clinical parameters of poor 
prognosis in HER2-positive breast cancer. Next, the analysis of three independent 
cohorts (totalizing 286 tumours) showed that approximately 65% of the HER2-
positive cases have GSDMB gene amplification and protein over-expression. Moreover, 
GSDMB expression was also linked to poor therapeutic responses in terms of lower 
relapse free survival and pathologic complete response as well as positive lymph node 
status and the development of distant metastasis under neoadjuvant and adjuvant 
treatment settings, respectively. Importantly, GSDMB expression promotes survival to 
trastuzumab in different HER2-positive breast carcinoma cells, and is associated with 
trastuzumab resistance phenotype in vivo in Patient Derived Xenografts. In summary, 
our data identifies the ERBB2 co-amplified and co-expressed gene GSDMB as a critical 
determinant of poor prognosis and therapeutic response in HER2-positive breast cancer.
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INTRODUCTION
The identification of molecular cancer drivers has 
considerably improved clinical outcomes in oncology. As 
such, inhibition of the human epidermal growth factor 
receptor 2 (HER2; ERBB2 gene) represents a paradigm in 
breast cancer oncology. Over-expression of ERBB2 occurs 
in approximately 20% of breast tumours [1, 2]. Thus, the 
amplification of chromosome 17q12-q21, which includes 
ERBB2, defines an intrinsic molecular cancer subtype 
associated with relatively aggressive tumour behaviour 
and poor clinical outcome [3]. However, the development 
of targeted anti-HER2 therapies based principally on 
humanized antibodies (such as trastuzumab, trastuzumab 
emtansine -T-DM1 or pertuzumab) and tyrosine kinase 
inhibitors (such as lapatinib) has dramatically improved 
the outcome of women with early and advanced stage 
HER2-positive breast cancer [4–11]. Several clinical trials 
have demonstrated that combination with chemotherapy 
in the neoadjuvant or adjuvant setting significantly 
improves clinical response without relevant toxicity 
[5, 13–16]. Despite the clinical benefit obtained from the 
above therapies, inhibition of HER2 alone is generally not 
sufficient. In fact, trastuzumab response rate is limited 
to approximately 15–26% [12, 13], which indicates 
the involvement of other molecules and/or signalling 
pathways that influence outcome in this setting [14]. 
Since the common 17q12-q21 amplicon includes 
several gene loci, ERBB2-co-amplified genes have been 
examined for their potential to influence cancer progression 
and/or therapeutic response [17,18]. A minimal amplified 
region around ERRB2 oncogene has been defined in several 
studies [19, 20], and some of the genes have been found 
to play a role in tumorigenesis [14, 21, 22]. These genes 
include STARD3 and GRB7, whose products promote the 
proliferation of HER2-positive breast cancer cell lines [18]. 
Thus, GRB7 over-expression has been identified as an 
independent prognostic factor [23], and the co-amplification 
of ERBB2 with the non-core gene topoisomerase II 
(TOP2A) predicts sensitivity to anthracycline therapy 
[21, 24, 25]. Together, these observations illustrate the 
importance of additional genes in the biology and clinical 
evolution of HER2-positive breast cancer.
Previous data demonstrated that GSDMB lies within 
the evolutionary recombination hotspot closely linked to 
the ERBB2 amplicon [20, 26]. The gene product belongs 
to the family of gasdermins, which includes three other 
human members [27–31]. Although these other members 
have been implicated in the development and progression 
of some diseases [32, 33], the role of GSDMB in cancer 
is only now beginning to emerge [30, 31, 34]. We recently 
demonstrated that GSDMB over-expression promotes 
cell motility, invasion and metastasis of breast cancer cell 
lines, and, intriguingly, it was found over-expressed in 
breast tumour samples [34]; however, the potential link 
with breast cancer subtypes remained unexplored. 
Here, through integrated gene expression and 
molecular analyses, we show robust associations between 
GSDMB amplification/expression and HER2-positive 
status. Most importantly, further analyses show that 
GSDMB gene and protein expression predicts poor clinical 
outcome in HER2-positive breast cancer treated, both in 
the neoadjuvant and adjuvant settings. Importantly, we 
corroborated that GSDMB expression is associated with 
trastuzumab resistance phenotype in HER2-positive 
breast carcinoma cells and in Patient Derived Xenografts. 
GSDMB increases cell growth and reduces apoptosis after 
trastuzumab treatment in breast cancer cells. Together, our 
data reveals GSDMB as a key prognostic and predictive 
biomarker in HER2-positive breast cancer, highlighting 
new opportunities for valuable combined therapies.
RESULTS 
GSDMB over-expression is associated with poor 
prognosis of HER2-positive breast cancer
We have previously reported that relative high 
expression of GSDMB, but no other GSDM genes, in breast 
tumours is associated with poor survival in unselected 
breast cancer cases [34]. To assess further the molecular and 
clinical significance of this observation, two independent 
microarray expression datasets including a total of 2,096 
cases were analysed [35, 36]. Overall, high GSDMB 
expression was correlated with HER2-positive status; 
according to the PAM50 classifier [37] or with the reported 
immunohistochemical results (Supplementary Table 1).
Next, the association between GSDMB over-
expression and 17q12-q21 amplification was evaluated. 
Using copy number estimates from The Cancer Genome 
Atlas (TCGA) dataset [36], the GSDMB locus was 
shown to be amplified in 58 out of 526 (11%) tumours. 
Importantly, this alteration was observed only in tumours 
that also presented ERBB2 amplification (58/67; 86%); 
thus, none of the 459 HER2-negative cases was identified 
as harbouring GSDMB amplification. Consistent with 
this observation, high GSDMB expression levels 
were associated with both ERBB2 and GSDMB gene 
amplification (Supplementary Table 1). 
Given the above correlations, and the role of 
GSDMB in promoting an aggressive breast cancer cell 
phenotype [34], we next assessed if the over-expression 
of GSDMB could also influence the prognosis of HER2-
high tumours. As shown in Figure 1, GSDMB over-
expression in these tumours was significantly associated 
with poor outcome: shorter disease free survival (DSF) 
and distant metastasis-free survival (DMFS) in the Ur-
Rehman dataset (p < 0.001, Figure 1A–1B); as well as 
overall survival (OS) in the TCGA dataset (p < 0.01, 
Figure 1C). Additionally, the prognosis value of GSDMB 
in these datasets was not independent of tumor grade. The 
association with poor prognosis was significantly stronger 
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(higher Hazard Ratios) in HER2-high cancers than in 
unselected breast cancers (whole dataset, Figure 1D).
Furthermore, we analysed the prognostic value of 
other 22 genes located near ERBB2. As shown in Figure 1D, 
over-expression of GSDMB represented the largest effect 
relative to poor prognosis (Figure 1D). 
Complementarily, to confirm further the association 
of GSDMB expression with poor prognosis we evaluated 
an additional series of 58 HER2-positive (by FISH 
and IHC) breast cancers [38]. Again, higher GSDMB 
expression associates significantly with shorter OS (log-
rank p = 0.002) (Supplementary Figure 1). 
Collectively, consistent results across different 
datasets demonstrate that high GSDMB expression 
identifies the most aggressive HER2+ breast tumours.
GSDMB is amplified and over-expressed in 
HER2-positive breast tumours
Our in silico analyses indicates that GSDMB 
over-expression is associated with the HER2-positive 
phenotype in breast cancer. To confirm this observation, 
the copy number status of the GSDMB locus was 
determined by FISH (Figure 2A) in a cohort of 53 breast 
cancer patients including HER2-positive (n = 29) and 
HER2-negative (n = 24) tumours classified according 
to the ERBB2 amplification status (“discovery series” in 
Supplementary Table 2). Thus, GSDMB amplification 
was detected in 21 tumours, and 15 of them (71.4%) 
were HER2-positive cases, therefore confirming the 
association between the both amplifications (p = 0.034, 
Table 1, Figure 2A, panel d). In the six cases classified as 
HER2-negative tumours showing GSDMB amplification, 
the HER2/centromere ratio was 1.9 + 0.24, suggesting the 
presence of HER2 aneuploidy [39].
Next, to determine if GSDMB amplification leads 
to over-expression of the corresponding product, an 
anti-GSDMB monoclonal antibody was developed. 
The antibody was able to recognize all the isoforms 
of GSDMB described [34] by Western blot analysis 
(Supplementary Figure 2 and Materials and Methods) 
and by immunohistochemistry (IHC). Thus, IHC assays 
revealed positive expression of GSDMB in 23 of the 
52 cases (44.2%; Figure 2B, Table 1). Importantly, this 
positivity was significantly correlated with ERBB2 gene 
amplification (16/23, 69.6%, p = 0.040, Table 1) and 
GSDMB amplification (p < 0.001; Table 1). In fact, intense 
GSDMB staining (Figure 2B, panel f) was found in HER2-
positive tumours with clear GSDMB gene amplification 
(Figure 2A, panel d, more than 10 signals/nucleus); while 
Figure 1: GSDMB over-expression is associated with poor prognosis in ERBB2-high breast cancers. Tumor samples 
with the top 25% expression levels of GSDMB gene (“high”) show significantly worse prognosis than the remaining tumors (“low”). 
(A) Disease-free survival and (B) Distant metastasis-free survival curves in breast cancers over-expressing (top 25%) ERBB2 from the Ur-
Rehman dataset [35]. (C) Overall patient survival curves for ERBB2-high tumors in the TCGA dataset [36]. Kaplan-Meier survival curves 
were generated and differences in survival were assessed by log-rank test (p < 0.05 considered statistically significant) using GraphPad 
PRISM 6.0. (D) Survival analyses of 23 genes close to ERBB2 locus in breast cancers. Tumour samples with the top 25% expression levels 
of each gene (considered “high”) were compared to the remaining tumors (“low”). Kaplan-Meier survival curves were generated and 
differences in DFS and DMFS survival were assessed by log-rank Mantel-Cox test using GraphPad PRISM 6.0. Analyses were performed 
in the Ur-Rehman and the TCGA datasets with all tumours (n = 1, 102 and n = 493, respectively), and for HER2-high (HER2+) cancers 
only. The p value of each test was color-coded as indicated in the scale on the right. HR: Hazard ratio associated with GSDMB gene high 
expression in each dataset.
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undetectable or weak GSDMB staining was detected 
in normal breast tissue (Figure 2B, panel b) or lesions 
without ERBB2 or GSDMB amplification (GSDMB gene 
copy number of < 4 signals/nucleus, Figure 2A, panel c). 
Together, these data demonstrate that GSDMB is over-
expressed in a subset (~65%) of HER2-positive tumors, 
with gene amplification being most likely the mechanism 
responsible of this alteration.
Figure 2: GSDMB gene amplification and protein expression in HER2-positive breast cancer. (A) Representative breast 
tumours with positive and negative HER2 and GSDMB amplification. Panels a, c, e: represent an example of breast carcinoma HER2-
positive (red signal) without GSDMB amplification. Panels b, d, f: represent an example of case HER2-positive with GSDMB amplification 
(blue signal). The lower lane shows the merged image (e of a-c and f of b-d panels). Green signals represent CEP7. Magnification x 63x; 
insets x 120. (B) Immunohistochemical analysis of HER2 and GSDMB in normal tissue (panel a, b), and in breast carcinoma cases (panels 
c–f). Low or undetectable GSDMB staining was observed in normal breast tissue (b) or in lesions with GSDMB gene copy number of < 4 
signals/nucleus (d) (considered non-amplified tumours). Intense GSDMB staining in a case with > 10 GSDMB copy number (f) considered 
as GSDMB-positive tumour. Scale bar measures 100 micrometers.
Table 1: Relationship between GSDMB gene amplification/protein expression and HER2 oncogene 
in breast cancer “discovery series”
    HER2 amplification: *n (%)
 Negative Positive
GSDMB amplification (n = 52)
Negative (n = 31)
Positive (n = 21)
18 (58.1)
6 (28.6)
 13 (41.9)
 15 (71.4)
     p = 0.034
GSDMB expression (n = 52)
Negative (n = 29)
Positive (n = 23)
17 (58.6)
 7 (30.4)
12 (41.4)
16 (69.6)
    p = 0.040
   GSDMB amplification: *n (%)  
 Negative                   Positive
GSDMB expression (n = 52)
Negative (n = 29)
Positive (n = 23)
29 (100)
2 (8.7)
0
21 (91.3)
    p < 0.001
*n (%), number of analyzed cases and (percentage).
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GSDMB gene amplification or expression predict 
poor clinical response and relapse under neoadjuvant 
settings in HER2-positive breast tumors
The results of the gene expression analyses indicate 
that GSDMB over-expression associates with poor 
prognosis of HER2-positive breast cancer. Next, we 
assessed the influence of GSDMB gene amplification and/
or expression in the therapeutic response of this cancer 
subtype. First, the analysis of a series of 28 HER2-
positive tumours in the discovery series, treated with 
the neoadjuvant setting revealed an association between 
GSDMB amplification and the lack of pathologic complete 
response (pCR) (p = 0.001, Table 2a). All of the analysed 
samples who developed local or distant relapse during the 
clinical follow-up showed GSDMB gene amplification 
and/or protein expression, respectively (p = 0.030, 
Table 2a, 2b). 
In order to validate the above results, an independent 
cohort of 95 HER2-positive breast cancer cases treated 
with the same neoadjuvant regimens (“validation series”, 
Supplementary Table 2) was analysed. As expected, 
61.1% and 68.8% of the HER2-positive tumours showed 
GSDMB amplification and protein expression, respectively 
(Supplementary Table 3); in fact, a strong association 
between both variables was observed (p < 0.001; Table 2a). 
Importantly, the analysis of this series corroborated the 
association between GSDMB gene amplification/expression 
and poorer therapy response. Among the 37 non-responder 
tumours, 31 (83.8%) showed GSDMB gene amplification 
and 33 (89.2%) protein expression (Table 2a–2b). 
Conversely, few cases without GSDMB amplification 
(16.2%) or protein expression (10.8%) were classified as 
non-responders (p < 0.001, Table 2a–2b). In both series, 
we did not find a clear association between GSDMB and 
hormone receptors expression suggesting that GSDMB 
could be a hormone receptor-independent biomarker. 
Next, univariate Cox proportional hazard analyses in 
the validation series revealed that both variables, GSDMB 
amplification and GSDMB expression, are significantly 
associated with reduced DFS in the neoadjuvant setting: 
HR = 5.60, 95% CI 1.66–18.88, long-rank p = 0.0002; 
and HR = 6.75, 95% CI 1.57–28.73, long rank p = 0.0004, 
respectively (Figure 3, Table 3). The average time to 
relapse for the GSDMB amplified and non-amplified cases 
was 37 ± 11 and 67.3 ± 17 months, respectively (Table 3, 
Figure 3A). Similarly, GSDMB positive and negative cases 
identified by IHC presented an average time to relapse of 
34.5 ± 14 and 66.2 ± 18 months (Figure 3B). The Kaplan-
Meier and log-rank survival analyses further illustrate 
the significant difference in DFS between GSDMB-
positive and GSDMB-negative groups (Figure 3A, 3B). 
Together, these results indicate that GSDMB expression/
amplification, influences both tumour progression and the 
response to therapy in HER2-positive breast cancer within 
the neoadjuvant setting.
Clinical association of GSDMB with low therapy 
response in the adjuvant setting in HER2 -positive 
breast tumours
To evaluate further the influence of GSDMB 
expression on the clinical response, a series of 138 breast 
cases treated with adjuvant therapy were analysed, 
53 (41.1%) of these tumours were classified as HER2-
positive and were treated following standard adjuvant 
schedules (Supplementary Table 4). In this series, around 
51% of these HER2-positive samples also expressed 
GSDMB (Table 4). Next, significant associations between 
GSDMB expression and positive lymph node status 
(p = 0.013) as well as with the existence of distant metastasis 
(p = 0.001) were revealed (Table 4). Univariate Cox 
proportional hazard analysis confirmed the association with 
DFS: HR = 2.85, 95% CI 1.28–6.37, log-rank p = 0.007 
(Table 5). Thus, the average time to relapse for the GSDMB-
positive and -negative cases was 91.24 + 14.88 and 101.81 + 
9.51 months, respectively. The Kaplan-Meier and log-rank 
survival analyses further illustrate the difference in DFS 
between GSDMB-positive and GSDMB-negative cases in 
the adjuvant setting (p = 0.007; Figure 3C). 
Overall these results and our previous data 
firmly establishes GSDMB as a negative prognostic 
marker in HER2-positive breast cancer patients treated 
(trastuzumab plus chemotherapy) in both the neoadjuvant 
and adjuvant settings.
GSDMB promotes survival to trastuzumab treatment 
Finally, to assess if GSDMB expression was 
functionally involved in promoting survival to anti-
HER2 therapy we performed several complementary 
experimental approaches. First, we evaluated the potential 
role of GSDMB expression on trastuzumab response in 
HCC1954 cells in which endogenous GSDMB has been 
stably silenced by shRNAs [34]. This model is an example 
of trastuzumab-resistant HER2+ human breast cancer cell 
line [40]. Additionally, we generated GSDMB exogenously 
expressing cells using SKBR3 (Figure 4A), which are 
trastuzumab-responsive cells [40]. In both cell models, 
trastuzumab inhibition of cell growth (measured by Alamar 
Blue method) was significantly higher (~20%) in cells 
with low GSDMB expression (Figure 4B–4C). Moreover, 
GSDMB significantly increased cell survival to trastuzumab 
treatment, as demonstrated by the reduction in apoptosis in 
GSDMB-overexpressing SKBR3 cells compared to control 
cells (Figure 4D). Given that HCC1954 are intrinsically 
very resistant to trastuzumab (5 mg/ml) we could not test 
the effect on apoptosis in this cell line.
Second, to demonstrate the association of GSDMB 
with resistance in vivo we utilized six breast cancer Patient 
Derived Xenografts (PDX), a more clinically relevant model 
[41]. We used four HER2-positive breast cancer PDXs, 
two sensitive and two primary resistant to trastuzumab 
Oncotarget56300www.impactjournals.com/oncotarget
Table 2: Relationship between GSDMB amplification/expression and clinico-pathological features 
in HER2-positive breast cancer included in the discovery (n = 28) and validation series (n = 95)
Discovery series Validation series
(a)
GSDMB amplification: *n (%) GSDMB amplification: *n (%)
Negative Positive Negative Positive
ER expression
Negative
Positive 
6/9 (66.7)
7/19 (36.8)
3/9 (33.3)
12/19 (63.2)
    p = 0.142
11/35 (31.4)
26/60 (43.3)
24/35 (68.6)
34/60 (56.7)
    p = 0.176
PR expression 
Negative 
Positive
10/19 (52.6)
3/9 (33.3)
9/19 (47.4)
6/9 (66.6)
     p = 0.338
16/49 (32.7)
19/44 (43.2)
33/49 (67.3)
25/44 (56.8)
      p = 0.295
GSDMB expression
Negative
Positive
12/12 (100)
1/16 (6.2)
0 (0)
15/16 (93.8)
    p < 0.001
29/29 (100)
6/64 (9.4)
    0 (0)
58/64 (90.6)
     p < 0.001
pCR †
Responders 
Non-responders 
12/16 (75.0)
1/12 (8.3)
4/16 (25.0)
11/12 (91.7)
    p = 0.001
31/58 (53.4)
6/37 (16.2)
27/58 (46.6)
31/37 (83.8)
    p < 0.001
Relapse †
Negative 
Positive 
12/26 (57.1)
0 (0)
9/26 (42.9)
5/5 (100)
    p = 0.030
24/47 (51.1)
3/19 (15.8)
23/47 (48.9)
16/19 (84.2)
    p = 0.008
(b)
GSDMB expression: *n (%) GSDMB expression: *n (%)
Negative Positive Negative Positive
ER expression 
Negative 
Positive 
6/9 (66.7)
6/19 (31.6)
3/9 (79.5)
13/19 (68.4)
    p = 0.090
9/35 (25.7)
20/58 (34.5)
26/35 (74.3)
38/58 (65.5)
    p = 0.145
PR expression 
Negative 
Positive 
9 (47.4)
3 (33.3)
10 (52.6)
6 (66.7)
    p = 0.293
13/48 (27.1)
14/43 (32.6)
35/48 (72.9)
29/43 (67.4)
    p = 0.366
pCR†
Responders 
Non-responders 
11 (68.8)
1 (8.3)
5 (31,3)
11 (91.7)
    p = 0.002
25/56 (44.6)
4/37 (10.8)
31/56 (55.4)
33/37 (89.2)
    p < 0.001
Relapse†
Negative 
Positive 
11 (52.4)
0
10 (47.6)
5 (100)
    p = 0.033
21/46 (45.7)
2/19 (10.5)
25/46 (54.3)
17/19 (89.5)
    p = 0.006
The data refers to the available cases for each markers (a) Statistical analysis of GSDMB amplification in breast carcinoma 
samples included in discovery and validation series. (b) Statistical analysis of GSDMB IHC study in breast carcinoma samples 
included in discovery and validation series. *n (%), number of analyzed cases and (percentage). †pCR: pathological complete 
response when there is no invasive presence of tumour at the breast or ganglia level (< 0.1 mm) and Relapse as local or distant 
recurrence in HER2-positive tumours. 
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([42] and data not shown) and two HER2-negative PDX 
as control (Figure 4E). The PDXs that did not respond to 
trastuzumab in vivo exhibited higher mRNA (Figure 4E) and 
protein levels (Supplementary Figure 3) of GSDMB than 
trastuzumab-sensitive patients and HER2-negative PDXs. 
Next, one of the trastuzumab-sensitive PDX (PDX118) 
was treated in vivo (biweekly; 1 mg/ml) with trastuzumab 
to induce an acquired drug resistance [43]. In most of the 
resistant PDXs originated from PDX118, we observed a 
significant increase in GSDMB (but not HER2) levels, thus 
corroborating that its expression is specifically associated 
with in vivo resistance to trastuzumab (Figure 4F).
Altogether, these data demonstrate that GSDMB 
overexpression is functionally involved in promoting 
resistance to the anti-HER2 inmunotherapy trastuzumab, 
and this may explain its association with adverse clinical 
behaviour in HER2+ cancers.
DISCUSSION
Despite significant clinical benefits to trastuzumab 
in HER2-positive breast tumors, not all patients respond 
well to this therapy, and therefore experience disease 
recurrence and progression [44, 45], within a few months 
Table 3: Risk of relapse in HER2-positive tumour validation series according to GSDMB copy 
number or GSDMB immunohistochemistry results
Evaluation Non-relapsed
*n, %
Relapsed
*n, %
Average time to 
relapse (months) HR 95% CI p
FISH GSDMB (n, %)
 Amplified (37, 56.1%) 16 (43.2%) 21 (56.8%) 37.0 ± 11 5.60 1.66–18.88 0.0002
 Non-amplified (29, 43.9%) 26 (89.7%) 3 (10.3%) 67.3 ± 17
IHC GSDMB (n, %)
 Positive (42, 63.6%) 20 (47.6%) 22 (52.4%) 34.5 ± 14 6.75 1.57 – 28.77 0.0004
 Negative (23, 34.8%) 21 (91.3%) 2 (8.7%) 66.2 ± 18
Table 4: Relationship between GSDMB over-expression and clinic pathological features in adjuvant 
breast cancer series
GSDMB expression †n (%)
 Negative Positive
HER2 amplification (n = 127)
Negative (n = 74)
Positive (n = 53)
68 (91.9)
26 (49.1)
6 (8.1)
27 (50.9)
       p < 0.001
ER expression (n = 43) *
Negative (n = 15)
Positive (n = 28)
12 (80.0)
11 (39.3)
3 (20.0)
17 (60.7)
       p = 0.012
PR expression (n = 49) *
Negative (n = 13)
Positive (n = 36)
8 (61.5)
17 (47.2)
5 (38.5)
19 (58.2)
       p = 0.489
Lymph node status (n = 49)*
Negative (n = 22)
Positive (n = 27)
16 (72.7)
10 (37.0)
6 (27.3)
17 (63.0)
       p = 0.013
Distant metastasis (n = 46) *
Negative (n = 30)
Positive (n = 16)
22 (73.3)
3 (18.8)
8 (26.7)
13 (81.2)
       p = 0.001
*Only evaluated in HER2-positive breast carcinomas. †n (%), number of analyzed cases and (percentage).
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of therapy (median of 7.4 months) [8,13]. In this scenario, 
the mechanisms of resistance to HER2-targeted therapy are 
not completely understood [46], and this limitation includes 
the unknown role of 17q12-q21 genes linked to ERBB2.
Our study demonstrates that gasdermin B (GSDMB), 
mapped 175 kilo bases distal to ERBB2, is amplified and 
over-expressed in a subset (~60%) of HER2-positive 
breast tumours. Importantly, GSDMB gene and protein 
over-expression is significantly associated with poor 
clinical outcome, in terms of disease progression, relapse 
and response after neoadjuvant therapy (Table 2), as well 
as lymph node positivity and the development of distant 
Figure 4: GSDMB expression increases survival to trastuzumab treatment. (A) Analysis of GSDMB expression by western 
blot in SKBR3 cells (empty vector, Control) and GSDMB-overexpressing cells (GSDMB). GAPDH was used as a loading control. 
(B) Analysis of cell growth (measured with Alamarblue) in control and GSDMB-overexpressing SKBR3 cells treated with 1 mg/ml 
trastuzumab for 72 h; (C) Reduction of cell growth in control (shNTC) and GSDMB-silenced (two shRNAs) HCC1954 cells treated with 
5 mg/ml trastuzumab. (D)Analysis of cell death (measured with Annexin V and propidium iodide) in control and GSDMB-overexpressing 
SKBR3 cells 72 h after trastuzumab treatment. Bars represent mean + SEM of three independent experiments. (E) GSDMB and HER2 
mRNA expression in Patient Derived Xenografts (PDX) from HER2-negative (PDX01, 02) and HER2-positivie breast carcinomas. PDXs 
were classified as trastuzumab sensitive (PDX118, 173) or resistant (PDX67, 288) according to in vivo patient response [42]. (F) GSDMB 
and HER2 mRNA expression in a trastuzumab-sensitive PDX (PDX118) and its trastuzumab-resistant derived PDXs (T-R1-R5), obtained 
by chronic in vivo treatment with trastuzumab. mRNA values were normalized using GAPDH as housekeeping gene. Bars represent 
mean + SEM expression of three experiments by quantitative PCR.
Figure 3: GSDMB gene amplification and/or protein expression associates with relapse in HER2-positive breast 
cancer samples under neoadjuvant and adjuvant treatment regimens. Relapse-free survival curves in HER2-positive breast 
cancer patients (n = 95) treated with neoadjuvant settings in relation to (A) GSDMB gene amplification (p = 0.0002) and (B) GSDMB 
expression scored by immunohistochemistry (IHC, p = 0.0004). (C) Relapse-free survival curves in HER2- positive breast cancer patients 
(n = 53) treated with adjuvant settings in relation to GSDMB protein expression measured by IHC (p = 0.007). Statistical differences, HR 
and p-value, were calculated via log-rank test. Red line: GSDMB amplified and expressed patients, green line: patients without GSDMB 
amplification and expression.
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metastases in the adjuvant context (Table 4) independently 
of hormone receptors status. Notably, the estimated effect 
in the neoadjuvant setting is relatively high (HR > 5) and, 
hence, the average time to relapse is almost halved in cases 
with GSDMB amplification or GSDMB over-expression.
GSDMB belongs to the gasdermin family of 
proteins [47]. Four gasdermin (GSDM) gene members 
have been identified in humans (GSDMA-D) [48]. 
GSDM genes have been involved in secretion, 
proliferation and differentiation in various tissues [48], 
although their major role seems to be the regulation of 
diverse types of cell death. In fact, GSDMD has been 
reported to be a substrate of caspase 11, essential for the 
activation of pyroptosis as anti-bacterial innate immune 
defence [49–52] and GSDMA promotes cell death 
through autophagy and mitochondrial damage [49,50]. 
The cell-death promoting function of GSDMA, C and 
D, depends on the cleavage of their N-terminal portion 
[51]. Interestingly, GSDMB does not induce cell death, 
and its C-terminal region is able to reduce partially the 
cell death induced by GSDMA [50]. Consistently, our 
data in different breast cancer cell lines models as well 
as in tumor Patient Derived Xenografts (PDXs) indicate 
that GSDMB promotes cell survival to trastuzumab anti-
HER2 immunotherapy. Given that GSDMB alone does 
not affect cell growth [34], these results point out that 
GSDMB might be a negative regulator of cell death/
survival under certain conditions (anti-HER2 therapy). 
Additionally, we have previously shown that GSDMB 
over-expression in a breast cancer cell line increased 
tumorigenic and invasive behaviour [34]. Therefore, 
GSDMB is functionally involved in promoting aggressive 
tumour behaviour and reduced clinical response to anti-
HER2 therapies. It would be of interest in the future 
to decipher the exact molecular mechanisms by which 
GSDMB mediates these effects. 
In conclusion, our study has identified GSDMB as 
a relevant biomarker of poor prognosis that is also able 
to predict non-response to current standard therapy for 
HER2-positive breast cancer. Since GSDMB expression 
promotes cell survival to anti-HER2 treatment, the analysis 
of GSDMB gene status and/or GSDMB expression may 
lead to more precise molecular classification of this cancer 
subtype and, in turn, help to identify cases that may not 
benefit from the current therapies.
MATERIALS AND METHODS
Tumour samples
A total of 286 paraffin-embedded ductal breast 
carcinoma included in this study was collected between 
2003 and 2014 at the Vall d’Hebron Hospital (Barcelona), 
Virgen del Rocío Hospital (Seville, Spain) and the MD 
Anderson Cancer Centre (Madrid). This study was 
approved by the local ethical committee from each 
institution, and a complete written informed consent 
was obtained from all patients. Briefly, this study was 
performed in two independent data samples treated under 
neoadjuvant treatment: discovery series, which included 29 
HER2 positive and 24 HER2 negative breast carcinomas, 
and validation series composed by 95 HER2 positive 
breast carcinomas (Supplementary Tables 2 and 3). The 
median age of patients and tumour size was 53.2 ± 14.9 
years and 2.23 ± 1.45 cm, respectively. Additionally, 
we studied 138 high-grade ductal breast tumours (52 
HER2-positive and 86 HER2-negative samples) all of 
them treated with adjuvant schedules (Supplementary 
Table 4). The mean age of patient and tumour size 
at surgery was 59.6 ± 9,1 years and 1.69 ± 0.42 cm, 
respectively. HER2 positivity was considered when 
the tumours showed gene amplification. All cases were 
treated with trastuzumab plus chemotherapy (based on 
a combination of anthracyclines and taxanes). Hormone 
therapy was added in those cases with positive hormone 
receptor expression. The clinical response of HER2-
positive cases in the neoadjuvant setting was evaluated 
using the pathological complete response criteria (pCR). 
The pCR was assessed at the breast parenchyma and at 
the ganglia level. A patient will be deemed to be in pCR 
when there is no invasive presence of tumour at the breast 
or ganglia level.
Immunohistochemistry (IHC) and Fluorescence 
in situ hybridization (FISH) analysis
HER2, ER (oestrogen receptor) and PR 
(progesterone receptor) were analysed by IHC in 
TMAs and in a complete section samples from PDXs, 
according to standard methods as previously published 
[40]. GSDMB monoclonal antibody was generated as 
Table 5: Risk of relapse in HER2-positive breast tumours treated under adjuvant regimens 
according to GSDMB immunohistochemistry results
Evaluation Non-relapsed
*n, %
Relapsed
*n, %
Average time to relapse 
(months) HR 95% CI p
IHC GSDMB (n, %)
  Positive (28, 45.2%) 7 (11.3%) 21 (33.9%) 91.24 ± 14.88 2.85 1.28–6.37 0.007
  Negative (34, 54.8%) 17 (27.4%) 17 (27.4%) 101.8 ± 9.51
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described in Supplementary Information, and GSDMB 
expression was classified as positive when more than 10% 
of tumour cells showed positive cytoplasmic staining. All 
studied tumour sections also included normal breast tissue 
as an internal control. In negative controls, the primary 
antibodies were omitted. FISH study was performed 
as previously described [53]. Briefly, the analysis was 
carried out simultaneously using red-labelled ERBB2, 
green-labelled chromosome enumeration probe (CEP17) 
as control (PathVysion Kit, Abbott Molecular), and aqua-
labelled GSDMB. The GSDMB probe was generated 
from DNA isolated from the bacterial artificial clone 
(BAC) RP11–387H17 obtained from the BACPAC 
Resource Centre (BPRC) at the Children’s Hospital 
Oakland Research Institute (CA, USA) and labelled by 
nick translation. Fluorescence signals were scored in each 
sample by counting the number of single copy genes and 
control probe signals in an average of 180 (100–210) 
well-defined nuclei. The ASCO CAP 2007 criteria for 
ERBB2 gene amplification [39] were used to evaluate the 
status of GSDMB gene. Increased gene copy number and 
amplification were defined as the presence of 4–6 and 
> 6 signals, respectively. The GSDMB/CEP17 ratio used 
to delimit amplification was of ≥ 2.2 [39].
GSDMB expression analysis in breast cancer 
microarray datasets
To evaluate the expression of GSDMB in breast 
tumours, several independent datasets were analyzed [35, 
36, 38] Microarray and clinical data were obtained from 
the ICR database (www.rock.icr.ac.uk). For each gene, 
normalized expression was categorized as “high” when it 
was above the third quartile (top 25% expression) of all 
tumour samples; otherwise, it was categorized as “low”. 
Kaplan-Meier estimates of GSDMB expression (assessed 
separately for each stratum) were plotted and compared 
to overall survival (OS), disease-free survival (DFS) and 
metastasis-free survival (MFS) curves using log-rank and 
Chi-square tests. 
Cell lines and Patient Derived Xenografts 
(PDXs)
For the study of the role of GSDMB in response 
to trastuzumab two well-studied HER2-positive breast 
cancer cell lines [40], HCC1954 and SKBR3, were used. 
Both cell lines were obtained from the American Type Cell 
Culture (ATCC). Cells were grown as monolayer cultures 
at 37ºC in an atmosphere with 5% CO2 and authenticated 
by STR-profiling according to ATCC guidelines. For the 
analysis of GSDMB over-expression, SKBR3 cells were 
stably transfected using Lipofectamine (Invitrogen) with 
pEZ-M61-GSDMB (Genecopoeia) or the empty vector. 
Cells containing the plasmids were selected with G418 
(0,8 mg/ml) treatment. GSDMB-silenced HCC1954 cells 
were obtained as previously reported [34]. HER2-positive 
and trastuzumab resistant Patient Derived Xenografts 
(PDXs) were previously described in [42, 43]. HER2-
negative PDXs were obtained from primary triple-negative 
breast tumours after engrafting orthotopically in the 
mammary fat of female athymic (nu/nu) mice (HarlanTM). 
The patients provided written informed consent nd the 
study was approved by IDIBELL Ethics committee. All 
ortho-xenograft models were established for > 3 passes. 
Their triple negative status was confirmed following 
standard inmmunohistochemical assays.
Cell-based assays
Trastuzumab anti-proliferative effects were 
measured in 2 × 103 cells plated on 96-well-plates using 
alamarBlue assay (Thermo Scientific) according to the 
manufacturer’s protocol. HCC1953 and SKBR3 cells 
were daily treated up to 72 h with 5 mg/ml and 1 mg/ml 
trastuzumab (Roche Diagnostics GmbH, Penzberg, 
Germany), respectively, or were left untreated. For 
detection of the death rate, SKBR3 cells were pre-treated 
in 0,1% FBS-containing medium during 24 h, and then 
(50 × 103.000 cells) cells were cultured in 6-well plates and 
treated with or without trastuzumab (1 mg/mL dissolved 
in medium) for 72 hours. Cell death was measured by 
staining with Annexin V and propidium iodide (PI) using 
PE-Apoptosis Detection kit (Immunostep) according 
to the manufacturer’s instructions, and analyzed on a 
FACSCANTO II flow cytometer (BD Biosciences). Three 
independent experiments were performed for Alamar blue 
and Cell death measurements. 
Gene expression assays
Gene expression was performed after extraction 
of total RNA from PDXs using RNA miniprep 
system, ReliaPrepTM FFPE total (Promega) following 
manufacturer recommendations. cDNA was obtained 
from 1 µg of total RNA using random primers and 
M-MLV reverse transcriptase (Amresco) as manufacturer 
recommendations. GSDMB, HER2, and GAPDH 
gene expression levels were measured by quantitative 
real time RT-PCR (qRT-PCR) using pre-designed 
TaqMan probes (Thermofisher) and PerfeCTa FastmixII 
(Quanta BioSciences, Inc), on an iQ5 iCycler Realtime 
PCR Detection System (BioRad), according to the 
manufacturer’s recommendations. All qRT-PCRs were 
performed in triplicate. Relative GSDMB and HER2 
expression was normalized to GAPDH. 
Statistical analysis
The χ2 or Fisher’s exact tests were used to test 
associations between categorical variables. All tests were 
two-tailed and 95% confidence intervals (CIs) were used. 
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Values of p < 0.05 were considered statistically significant. 
Hazard ratios (HRs) and 95% CIs were estimated from 
univariate or multivariate Cox proportional hazards models. 
Disease-free survival was defined as the time from the date 
of diagnosis to the date of recurrence or development of 
novel distant metastasis. Survival curves were generated 
using the Kaplan-Meier method. The p-values are based on 
the Wald test for Cox proportional hazards models, and the 
log-rank test for Kaplan-Meier analysis. Statistical analysis 
were performed in R and using the Survival package and 
SPSS Statistics 17.0 (SPSS Inc., Chicago, IL). 
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